CYT387: A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis

Pamiparib : Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial

MLN7243 : Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma